NCT01301573终止不适用
Long Term Follow-Up Study for rAAV-GAD Treated Subjects
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 40
- 试验地点
- 6
研究概览
简要总结
The purpose of this observational study is the long term follow-up of Parkinson's patients who participated in a clinical trial in which they received AAV-GAD gene transfer into the subthalamic nucleus (STN) region of the brain. Patients will be followed once a year for up to five (5) years. The study will monitor and evaluate the long term effects of AAV-GAD and provide long term safety information.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 30 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participated in a clinical trial where they received AAV-GAD
- •Able to give informed consent to participate in the study
排除标准
- •Received Deep Brain Stimulation after receiving AAV-GAD
- •Received any experimental device in the brain after receiving AAV-GAD
- •Had any type of brain surgery after receiving AAV-GAD
- •Received any experimental therapy (drug or biologic) for Parkinson's disease or any other indication after receiving AAV-GAD
研究者
研究点 (6)
Loading locations...
相似试验
进行中（未招募）
不适用
Long Term Follow-up of Patients With Parkinson's Disease Who Had Administered of A9-DPC in SB-PD-001 StudyParkinson's DiseaseNCT06477744S.Biomedics Co., Ltd.12
Unknown
不适用
An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCIDAdenosine Deaminase DeficiencySevere Combined Immunodeficiency (SCID)NCT04049084University of California, Los Angeles70
进行中（未招募）
不适用
Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced XerostomiaRadiation-induced XerostomiaNCT05060341MeiraGTx, LLC22
终止
不适用
Observational Natural History Study of Autosomal Dominant Retinitis Pigmentosa (adRP)Retinitis PigmentosaNCT02926092Shire1
Enrolling By Invitation
不适用
A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal InjectionRetinitis PigmentosaRetinal DiseaseRetinal DegenerationNCT05921162Nanoscope Therapeutics Inc.11